- Home
- ยป
- Our Products
- »
- Pharmaceutical Tablets
Pharmaceutical Tablets
10mg Ambrisun Ambrisentan Tablet
Product Brochure
| Strength | 10 mg |
| Packaging Size | 1x10 tablets |
| Packaging Type | Box |
| Brand | Sunrise |
| Shelf life | 24 Months |
10mg Ambrisentan Tablet
Minimum Order Quantity: 10 Strip
Product Brochure
| Strength | 10 mg |
| Packaging Size | 10 Tab |
| Packaging Type | Box |
| Composition | Endobloc 10mg |
| Brand | Cipla |
| Shelf life | 2 Years |
Description:
Ambrisentan is an endothelin receptor antagonist used to treat pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the lungs' arteries. It works by blocking endothelin-1 receptors, which are responsible for constricting blood vessels. By inhibiting endothelin-1, Ambrisentan helps relax and widen the blood vessels, thereby reducing pulmonary artery pressure and improving blood flow to the lungs. This results in improved exercise capacity and symptoms in patients with PAH.
Pulmonary Arterial Hypertension (PAH):
Ambrisentan is primarily used to treat PAH, either alone or in combination with other medications, to help reduce pulmonary artery pressure and improve overall lung function.To Improve Exercise Capacity:
Ambrisentan helps improve exercise tolerance and symptoms like shortness of breath in patients with PAH.
Dosage:
The usual starting dose is 5 mg once daily. Depending on patient tolerance, the dose may be increased to 10 mg once daily. The maximum recommended dose is 10 mg per day.Administration:
Ambrisentan is taken orally in tablet form, with or without food. It is typically prescribed as a once-daily dose. It’s important to follow the prescribed dosage regimen as directed by your healthcare provider.
- Headache
- Edema (swelling), especially in the legs and ankles
- Flushing
- Anemia (low red blood cell count), which may cause fatigue
- Liver enzyme abnormalities
- Nausea or stomach upset
Liver Function Monitoring:
Ambrisentan can cause liver enzyme elevations, so it is important to monitor liver function regularly during treatment.Pregnancy:
Ambrisentan can cause harm to an unborn baby. It is contraindicated during pregnancy, and women of childbearing age must use effective contraception during treatment.Anemia:
Ambrisentan may cause or worsen anemia, so regular blood tests to monitor red blood cell levels are recommended.Fluid Retention:
Patients should be monitored for signs of fluid retention, as Ambrisentan may cause swelling or edema, particularly in the legs, ankles, or abdomen.Kidney or Heart Disease:
Use with caution in patients with a history of kidney or heart issues. Consult your healthcare provider for advice on whether Ambrisentan is suitable for you.
Ambrisentan 10 mg is an effective treatment for pulmonary arterial hypertension (PAH), helping to lower pulmonary artery pressure and improve exercise capacity and symptoms. With careful monitoring for potential side effects such as liver abnormalities, anemia, and fluid retention, Ambrisentan provides a targeted approach to managing PAH. Treatment plans should be customized by healthcare professionals to achieve the best therapeutic outcomes.
Ambrisun Ambrisentan 5 mg Tablets
Product Brochure
| Strength | 5 mg |
| Packaging Size | 1*10 Tablets |
| Composition | Ambrisentan IP 5 mg |
| Brand | Ambrisun |
| Manufacturer | Sunrise Remedies |
| Treatment | Pneumonic blood vessel hypertension (PAH) |
Ambrisentan Tablets (Ambrican 5 mg Tablets)
Product Brochure
| Strength | 5 mg |
| Packaging Size | 10 Tablets in 1 Strip |
| Composition | Ambrisentan 5 mg |
| Brand | Ambrican |
| Manufacturer | Lupin Ltd |
| Treatment | Pulmonary arterial hypertension (PAH) |
Ambrisentan Tablets (Ambrican 5 mg Tablets)
Overview:
Ambrisentan 5 mg Tablets contain Ambrisentan, a selective endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH). PAH is a condition where the blood pressure in the arteries of the lungs is abnormally high. Ambrisentan works by blocking endothelin receptors, which normally cause blood vessels to constrict. By inhibiting these receptors, Ambrisentan helps dilate the pulmonary arteries, improving blood flow and reducing the workload on the heart.
Indications:
Ambrisentan 5 mg Tablets are indicated for:
- Pulmonary Arterial Hypertension (PAH): To improve exercise capacity and delay clinical worsening in patients with PAH. It can be used alone or in combination with other treatments, such as sildenafil.
Mechanism of Action:
Ambrisentan selectively blocks endothelin receptors (ET-A), which are involved in vasoconstriction. By inhibiting these receptors, Ambrisentan reduces pulmonary vascular resistance and lowers pulmonary artery pressure, thus improving oxygenation and reducing the strain on the right side of the heart. This leads to improved exercise tolerance and quality of life in patients with PAH.
Dosage and Administration:
- Recommended Dose: The usual starting dose is 5 mg once daily.
- Administration: Ambrisentan can be taken with or without food. It should be swallowed whole with water. The dose may be increased to 10 mg once daily based on the patient's response and tolerability.
Side Effects:
- Common Side Effects: Swelling (edema), headache, nasal congestion, flushing, and mild anemia.
- Serious Side Effects: Liver function abnormalities, low blood pressure, and fluid retention. Regular monitoring of liver enzymes and blood pressure is recommended.
Precautions:
- Liver Function: Ambrisentan can affect liver enzymes, so liver function should be monitored before and during treatment.
- Pregnancy: Ambrisentan is contraindicated during pregnancy due to potential risks to the fetus. A negative pregnancy test is required before starting treatment, and women of childbearing potential should use effective contraception.
- Fluid Retention: Caution should be used in patients with a history of heart failure or significant fluid retention.
Storage:
Store Ambrisentan 5 mg Tablets at room temperature (15°C to 30°C), away from light and moisture, and out of the reach of children.
Conclusion:
Ambrisentan 5 mg Tablets are an effective treatment for pulmonary arterial hypertension. By blocking endothelin receptors, Ambrisentan helps improve pulmonary blood flow and exercise capacity. However, it requires careful monitoring, especially for liver function and fluid retention. Regular follow-up with healthcare providers is crucial for safe and effective treatment.
12mg Iverheal Ivermectin Tablet
Minimum Order Quantity: 10 Box
Product Brochure
| Strength | 12mg |
| Packaging Size | 1*10 Tablets |
| Usages | Parasitic Infection Treatment |
| Brand | Healing Pharma |
| Form | Tablet |
| Shelf Life | 2 Years |
| Pack Size | 10x10 Tablet |
| Pack Type | Box |
Medicine brandIverhealMedicine formTabletMedicine nameIvermectin tablets uspMedicine strength12 mgPackaging size10 x 10 tabletsSalt compositionIvermectin
2mg Progynova Estradiol Tablet
Product Brochure
| Strength | 2 mg |
| Packaging Size | 28 Tablets in 1 Strip |
| Composition | Estradiol 2 mg |
| Brand Name | Progynova |
| Manufacturer | Bayer Zydus Pharma Pvt Ltd |
| Treatment | Hormone Replacement Therapy |
2 mg Progynova Estradiol Tablet
Overview:
Progynova 2 mg (Estradiol) is a synthetic form of estradiol, a type of estrogen, used primarily in hormone replacement therapy (HRT) for menopausal symptoms and estrogen deficiency. It helps to alleviate common symptoms of menopause such as hot flashes, vaginal dryness, and osteoporosis. Progynova is also used in cases of hypoestrogenism, where the body does not produce enough estrogen, and can be part of HRT regimens for women who have undergone a hysterectomy.
Indications:
Progynova 2 mg is prescribed for:
- Menopausal Symptoms: To treat hot flashes, mood changes, and vaginal dryness due to the reduction of estrogen levels after menopause.
- Osteoporosis Prevention: To reduce bone loss and the risk of fractures in postmenopausal women.
- Hypoestrogenism: For women with estrogen deficiency due to ovarian failure, premature menopause, or hormonal imbalances.
- Hormone Replacement Therapy (HRT): For women who have had a hysterectomy, to balance hormone levels and manage symptoms related to low estrogen.
Mechanism of Action:
Estradiol, the active ingredient in Progynova, binds to estrogen receptors in various tissues such as the reproductive organs, bones, and cardiovascular system. It helps regulate vital functions like the menstrual cycle, bone density, and cardiovascular health. By replenishing estrogen, Progynova eases menopause-related symptoms and protects bone health by preventing osteoporosis.
Dosage and Administration:
- Recommended Dose: Typically, 2 mg daily is prescribed. The dose may be adjusted based on response.
- Administration: Taken orally, with or without food, as part of a hormone replacement therapy regimen.
- Duration: The length of treatment depends on individual needs and response.
Side Effects:
- Common Side Effects: Nausea, headache, weight gain, breast tenderness, and bloating.
- Serious Side Effects: Increased risk of blood clots, stroke, heart disease, and endometrial cancer (especially when used without a progestogen).
Precautions:
Progynova should be used cautiously in women with a history of breast cancer, liver disease, or blood clots. Regular monitoring for blood pressure, liver function, and bone health is advised. Pregnancy and breastfeeding are contraindications.
Storage:
Store at room temperature (15°C to 30°C) away from light and moisture.
Conclusion:
Progynova 2 mg is an effective treatment for managing menopausal symptoms and preventing osteoporosis. Regular monitoring is essential for managing risks associated with long-term use.
50mg Instgra Dolutegravir Tablets
Product Brochure
| Dose Strength | 50 mg |
| Packaging Size | 30 Tablets in 1 Bottle |
| Composition | Dolutegravir |
| Brand Name | Instgra 50 mg |
| Manufacturer | Emcure Pharmaceuticals Ltd |
| Treatment | HIV Infection |
Instgra (Dolutegravir) 50 mg Tablets
Overview: Instgra contains dolutegravir, an integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection. It is effective in reducing viral load and improving immune function as part of a comprehensive antiretroviral therapy regimen.
Indications:
- HIV Infection: Indicated for the treatment of HIV-1 infection in adults and pediatric patients aged 12 years and older, as part of a combination therapy.
Mechanism of Action: Dolutegravir inhibits the integrase enzyme, which is essential for the integration of viral DNA into the host genome. This action prevents the replication of the virus, effectively reducing its presence in the body.
Dosage and Administration:
- Recommended Dose: The usual dose is 50 mg taken orally once daily. In some cases, it may be taken twice daily based on specific patient factors.
- Administration: Can be taken with or without food. Consistency in timing is important for optimal effectiveness.
Side Effects: Common side effects may include:
- Insomnia
- Headache
- Fatigue
- Nausea
- Diarrhea
- Weight gain (in some patients)
Warnings and Precautions:
- Hypersensitivity Reactions: Monitor for signs of serious allergic reactions, including skin rash or liver problems.
- Liver Function: Patients with a history of liver disease should be closely monitored.
- Drug Interactions: Dolutegravir may interact with other medications, particularly those affecting liver enzymes. Discuss all current medications with a healthcare provider.
Contraindications:
- Hypersensitivity to dolutegravir or any components of the formulation.
- Not recommended during pregnancy unless the benefits outweigh the risks.
Drug Interactions: Dolutegravir may interact with various medications, especially those that influence CYP450 enzymes. It’s crucial to discuss all medications and supplements with a healthcare provider.
Storage Instructions: Store at room temperature, away from moisture and light. Keep out of reach of children.
Patient Counseling Information:
- Advise patients to take the medication as prescribed and not to miss doses to maintain viral suppression.
- Discuss the importance of regular follow-up appointments for monitoring HIV viral load and overall health.
- Instruct patients to report any unusual side effects, particularly severe allergic reactions.
Instgra (Dolutegravir) 50 mg Tablets are an effective option for managing HIV-1 infection. Proper adherence to dosing, monitoring for side effects, and patient education are essential for optimizing treatment outcomes. Always consult a healthcare provider for personalized treatment recommendations.
Tenof em 300mg/200mg Tablet (Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg)
Product Brochure
| Dose/Strength | 300mg/200mg |
| Packaging Size | 1x30Tablets |
| Strength | Tenofovir Disoproxil 300 mg, Emtricitabine 200 mg |
| Brand Name | Tenof EM |
| Manufacturer By | Hetero Drugs Ltd |
| Treatment | HIV Infection |
Tenof EM Tablet (Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg)
Overview: Tenof EM is a fixed-dose combination tablet that contains tenofovir disoproxil fumarate and emtricitabine. It is used for the treatment of HIV-1 infection and for pre-exposure prophylaxis (PrEP) in individuals at high risk of HIV infection.
Indications:
- HIV Infection: For the treatment of HIV-1 infection in adults and pediatric patients as part of a comprehensive antiretroviral therapy regimen.
- Pre-exposure Prophylaxis (PrEP): For individuals at high risk of HIV to reduce the risk of acquiring the virus.
Mechanism of Action:
- Tenofovir Disoproxil Fumarate: A nucleotide reverse transcriptase inhibitor (NRTI) that inhibits the reverse transcriptase enzyme, preventing the conversion of viral RNA into DNA.
- Emtricitabine: A nucleoside reverse transcriptase inhibitor (NRTI) that also works by inhibiting reverse transcriptase, thus reducing viral replication.
Dosage and Administration:
- Recommended Dose: Typically, one tablet taken orally once daily.
- Administration: Can be taken with or without food. It is important to take it at the same time each day for maximum effectiveness.
Side Effects: Common side effects may include:
- Nausea
- Diarrhea
- Fatigue
- Headache
- Possible kidney function changes (particularly with tenofovir)
Warnings and Precautions:
- Renal Function: Regular monitoring of kidney function is important, especially in patients with pre-existing kidney issues.
- Liver Function: Monitor liver function, particularly in patients with a history of liver disease.
- Bone Health: Long-term use may affect bone mineral density; monitoring may be necessary.
Contraindications:
- Hypersensitivity to any of the components.
- Severe renal impairment.
Drug Interactions: Tenof EM may interact with other medications, particularly those affecting kidney function or renal excretion. Patients should inform their healthcare provider about all medications and supplements they are taking.
Storage Instructions: Store at room temperature, away from moisture and light. Keep out of reach of children.
Patient Counseling Information:
- Advise patients to take the medication as prescribed and not to miss doses.
- Discuss the importance of regular follow-up appointments for monitoring viral load and kidney function.
- Instruct patients to report any unusual side effects, especially related to kidney health or gastrointestinal symptoms.
Tenof EM Tablet (Tenofovir Disoproxil Fumarate and Emtricitabine) is an effective treatment option for managing HIV-1 infection and for PrEP. Proper adherence to dosing, monitoring for side effects, and patient education are essential for optimizing treatment outcomes. Always consult a healthcare provider for personalized treatment recommendations.
100mg Imalek Imatinib Mesylate Tablets
Product Brochure
| Dose/Strength | 100 mg |
| Form | Tablet |
| Packaging Size | 10 Tablets |
| Packaging Type | Box |
| Shelf Life | 2 Yearsd |
| Usage | Cancer Treatment |
| Brand Name | Sun Pharma |
Imalek Imatinib 100mg Tablets
Overview:
Imalek (Imatinib 100mg Tablets) is an oral medication used to treat various cancers, primarily chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), and gastrointestinal stromal tumors (GISTs). Imatinib is a tyrosine kinase inhibitor that works by blocking abnormal proteins responsible for cancer cell growth, which helps prevent the spread of cancer.
Indications:
Imalek 100mg Tablets are indicated for:
- Chronic Myelogenous Leukemia (CML): For newly diagnosed or chronic phase CML.
- Acute Lymphoblastic Leukemia (ALL): Specifically for Philadelphia chromosome-positive (Ph+) ALL.
- Gastrointestinal Stromal Tumors (GISTs): For unresectable or metastatic GISTs expressing the KIT protein.
- Other cancers: Includes hypereosinophilic syndrome and chronic eosinophilic leukemia.
Mechanism of Action:
Imatinib targets and inhibits BCR-ABL tyrosine kinase, an enzyme produced by cancer cells, particularly in CML. This enzyme is crucial for cancer cell growth. By blocking it, Imatinib prevents the signaling pathways that promote cell division, leading to tumor shrinkage and cancer cell death.
Dosage and Administration:
- Recommended Dose: For CML, the usual dose is 400 mg daily, taken with food. For GISTs, doses range from 400 mg to 800 mg based on patient response.
- Administration: Take once daily, with or without food.
- Missed Dose: If missed, take as soon as possible unless it's near the next dose. Do not double the dose.
Side Effects:
Common effects include nausea, vomiting, diarrhea, muscle cramps, and fatigue. Serious effects can include hepatotoxicity, cardiac problems, bone marrow suppression, and allergic reactions.
Precautions:
- Heart conditions: Caution in patients with heart disease.
- Liver function: Monitor liver enzymes.
- Pregnancy: Contraindicated due to potential fetal harm.
Monitoring:
Regular blood tests to monitor for anemia, thrombocytopenia, and liver function.
Storage:
Store at room temperature (20°C to 25°C) in a dry place. Keep out of reach of children.
Conclusion:
Imalek (Imatinib 100mg Tablets) is a highly effective treatment for cancers such as CML, ALL, and GISTs. Monitoring is essential for minimizing side effects.
Pirfenidone Pulmofib 267mg Tablets
Product Brochure
| Strength | 267 mg |
| Packaging Type | Box |
| Packaging Size | 10X10 Tablets |
| Brand | Pulmofib |
| Composition | Pirfenidone |
| Shelf Life | 2 Years |
Pirfenidone Pulmofib 267mg Tablets
Overview:
Pirfenidone (brand name Pulmofib 267mg Tablets) is an oral antifibrotic medication used in the treatment of idiopathic pulmonary fibrosis (IPF), a condition characterized by progressive scarring of the lungs. It works by reducing the production of certain fibrotic mediators that promote inflammation and fibrosis (scarring) in the lungs. By modulating the fibrotic process, Pirfenidone helps to slow the progression of IPF, improve lung function, and enhance patients’ quality of life.
Indications:
Pulmofib 267mg Tablets are indicated for:
- Idiopathic Pulmonary Fibrosis (IPF): To slow the progression of IPF in patients with mild-to-moderate disease.
- Other Fibrotic Conditions: May be used off-label for other fibrotic diseases under healthcare provider guidance.
Mechanism of Action:
Pirfenidone is an antifibrotic agent that targets multiple pathways involved in fibrosis. It inhibits the synthesis of TGF-beta (Transforming Growth Factor beta), a key cytokine involved in the fibrotic process. Additionally, Pirfenidone modulates pro-inflammatory cytokines and growth factors, thereby reducing inflammation and collagen deposition in lung tissues. This helps in reducing the formation of scar tissue, improving lung function, and slowing disease progression in IPF.
Dosage and Administration:
- Recommended Dose: The typical starting dose of Pirfenidone is 267 mg three times a day, gradually increasing to the target dose of 801 mg three times a day (for a total of 2403 mg/day) as tolerated.
- Administration: Take the tablets with food to improve absorption and reduce gastrointestinal side effects.
- Missed Dose: If a dose is missed, take it as soon as possible unless it’s close to the next dose. Do not take two doses at once.
Side Effects:
Common side effects include:
- Nausea, fatigue, diarrhea, loss of appetite, and rash.
Serious side effects may include: - Liver toxicity: Elevated liver enzymes and potential liver damage.
- Photosensitivity: Increased sensitivity to sunlight, leading to severe sunburn.
- Gastrointestinal issues: Severe nausea or vomiting.
Precautions:
- Liver Function: Regular monitoring of liver function tests is essential, especially in patients with a history of liver disease.
- Photosensitivity: Patients should avoid prolonged sun exposure and wear sunscreen.
- Pregnancy: The safety of Pirfenidone during pregnancy is not established. It should be used only if clearly needed.
Storage:
Store Pulmofib 267mg Tablets at room temperature (20°C to 25°C), away from moisture and light. Keep out of reach of children.
Conclusion:
Pirfenidone (Pulmofib 267mg Tablets) is an effective treatment for slowing the progression of idiopathic pulmonary fibrosis (IPF). By reducing lung inflammation and fibrosis, it helps maintain lung function and improve quality of life. Regular monitoring for side effects, particularly liver function, is essential for safe and effective treatment.
Rivofonate 300 Mg Tablets
Product Brochure
| Dose/Strength | 300 mg |
| Composition | Tenofovir Disoproxil Fumarate 300 mg |
| Packaging Size | 1x30Tablets |
| Brand Name | Rivofonate |
| Manufacturer By | Emcure Pharmaceuticals Ltd |
| Treatment | HIV Infection |
Overview
Rivofonate is a medication used primarily for the treatment of conditions related to bone health, particularly osteoporosis. It works to improve bone density and reduce the risk of fractures.
Indications
- Primary Use: Treatment and prevention of osteoporosis in postmenopausal women and in men at high risk of fractures.
Mechanism of Action
- Rivofonate is a selective estrogen receptor modulator (SERM) that mimics the effects of estrogen on bone tissue. It helps maintain bone density and strength by reducing bone resorption and turnover.
Dosage and Administration
- Typical Dosage: The usual dose is 300 mg taken once daily, but specific dosing may vary based on individual patient needs and medical advice.
- Administration: Take the tablet orally, preferably at the same time each day. It can be taken with or without food.
Side Effects
-
Common Side Effects:
- Hot flashes
- Nausea
- Headaches
- Muscle pain
- Back pain
-
Serious Side Effects:
- Increased risk of blood clots (deep vein thrombosis, pulmonary embolism)
- Liver function abnormalities
- Endometrial cancer (in women with a uterus)
Contraindications
- Hypersensitivity to Rivofonate or any components of the formulation.
- History of thromboembolic disorders.
- Pregnant or breastfeeding women.
Warnings and Precautions
- Monitor for signs of blood clots, particularly in patients with risk factors.
- Periodic liver function tests may be recommended during treatment.
- Discuss the benefits and risks with patients, especially those with a history of hormone-related cancers.
Storage
- Store at room temperature (15°C to 30°C), away from moisture and light.
Patient Counseling
- Instruct patients to take the medication as prescribed and report any unusual symptoms, particularly those suggesting blood clots (e.g., swelling, pain, shortness of breath).
- Encourage lifestyle changes that support bone health, such as adequate calcium and vitamin D intake, regular exercise, and avoiding smoking.
Conclusion
Rivofonate 300 mg tablets are an effective treatment option for osteoporosis. Adherence to prescribed dosages and awareness of potential side effects are essential for optimizing therapeutic outcomes. Always consult a healthcare provider for personalized advice and management during treatment.
2mg Estraheal Valerate Tablet
Product Brochure
| Strength | 2 mg |
| Usage/Application | Clinic |
| Form Of Medicines | Tablet |
| Packaging Type | Box |
| Pack Size | 1x28 Tablets |
| Shelf Life | 24 Months |
| Brand | Healing Pharma |
| Medicine brand | Estraheal |
| Medicine form | Tablet |
| Medicine name | Estradiol valerate tablets |
| Medicine strength | 2mg |
| Packaging size | 1 x 28 tablets |
Osimertinib Tablet (Tagrisso 40 mg Tablet)
Product Brochure
| Strength | 40 mg |
| Packaging Size | 30*1 Tablets |
| Composition | Osimertinib 40 mg |
| Brand | Tagrisso |
| Manufacturer | AstraZeneca |
| Treatment | Non-small Cell Lung Cancer |
| Medicine brand | Tagrisso |
| Medicine form | Tablet |
| Medicine name | Osimertinib tablets |
| Medicine strength | 40mg |
| Packaging size | 10 |
| Packaging type | Box |
100mg Dapsone Tablet
Product Brochure
| Strength | 100 mg |
| Packaging Size | 1000 Tablets |
| Compostion | Dapsone 100 mg |
| Brand Name | Dapsone |
| Manufactured By | Glaxosmithkline Pharmaceuticals Ltd |
| Treatment | Leprosy and Skin problems |
Overview: 100mg Dapsone Tablet contains Dapsone, an antibiotic primarily used to treat leprosy, dermatitis herpetiformis, and Pneumocystis jirovecii pneumonia (PCP) in immunocompromised patients, especially those with HIV/AIDS. Dapsone works by inhibiting the synthesis of folic acid in bacteria and parasites, which disrupts their ability to grow and reproduce.
Indications: Dapsone 100mg Tablet is indicated for:
- Leprosy: Treatment of multibacillary and paucibacillary leprosy in combination with other agents.
- Dermatitis Herpetiformis: Treatment of this chronic, autoimmune blistering skin disorder.
- Pneumocystis jirovecii pneumonia (PCP): Prophylaxis and treatment in immunocompromised patients, particularly those with HIV.
- Malaria: Off-label use for malaria, in combination with other drugs.
Mechanism of Action: Dapsone inhibits the enzyme dihydropteroate synthetase, which is involved in the synthesis of folic acid in bacteria and protozoa. This action prevents DNA and protein synthesis in the targeted organisms, thus limiting their growth and replication.
Dosage and Administration:
- Leprosy: Typically 100-200mg once daily, as part of a multidrug regimen.
- Dermatitis Herpetiformis: 50-100mg daily, adjusted based on patient response.
- PCP Prophylaxis/Treatment: 100mg daily for prophylaxis, and 100mg twice daily for treatment in immunocompromised patients.
Take the tablet with food to minimize gastrointestinal irritation.
Side Effects: Common side effects include:
- Hemolysis (especially in patients with G6PD deficiency), anemia, rash, and fever.
- Gastrointestinal disturbances: Nausea, vomiting, and loss of appetite.
- Peripheral neuropathy, headache, and dizziness.
Serious side effects may include:
- Severe skin reactions: Erythema multiforme, and Stevens-Johnson syndrome.
- Hepatic toxicity, methemoglobinemia, and blood dyscrasias (e.g., agranulocytosis).
Precautions:
- G6PD Deficiency: Use with caution as Dapsone can cause hemolysis in affected individuals.
- Blood Counts: Regular monitoring of blood counts is recommended, especially during prolonged treatment.
- Liver and Kidney Function: Monitor liver and kidney function regularly.
- Pregnancy/Breastfeeding: Use with caution during pregnancy and breastfeeding, as Dapsone may be excreted in breast milk.
Storage: Store at room temperature (20°C to 25°C), away from moisture and light. Keep out of reach of children.
Conclusion: 100mg Dapsone Tablet is an effective treatment for leprosy, dermatitis herpetiformis, and PCP in immunocompromised patients. Regular blood monitoring and caution in patients with G6PD deficiency are important to ensure safe and effective use.
1mg Progynova Estradiol Valerate Tablet
Product Brochure
| Strength | 1 mg |
| Pack Size | 28 Tablets in 1 Strip |
| Composition | Estradiol 1 mg |
| Brand Name | Progynova |
| Manufacturer | Bayer Zydus Pharma Pvt Ltd |
| Treatment | Hormone replacement therapy |
1 mg Progynova Estradiol Valerate Tablet
Overview:
Progynova 1 mg (Estradiol Valerate) is a synthetic estrogen used primarily in hormone replacement therapy (HRT) to treat symptoms of menopause and estrogen deficiency. Estradiol valerate, a prodrug of estradiol, is converted to active estradiol in the body. Progynova helps alleviate common menopausal symptoms such as hot flashes, vaginal dryness, and osteoporosis. It is also used in women with hypoestrogenism or ovarian failure to restore normal estrogen levels.
Indications:
Progynova 1 mg is indicated for:
- Menopausal Symptoms: To alleviate symptoms such as hot flashes, mood swings, and vaginal dryness caused by a decrease in estrogen after menopause.
- Osteoporosis Prevention: To reduce the risk of bone loss and fractures in postmenopausal women.
- Hypoestrogenism: In women with estrogen deficiency due to conditions like ovarian failure, premature menopause, or hormonal imbalances.
- Hormone Replacement Therapy (HRT): For women who have had a hysterectomy, estradiol is used to balance hormone levels and manage estrogen-related symptoms.
Mechanism of Action:
Estradiol valerate is a prodrug of estradiol, a form of estrogen, which binds to estrogen receptors in various tissues. This helps regulate functions such as the menstrual cycle, bone density, and cardiovascular health. By replenishing estrogen, Progynova relieves symptoms associated with menopause and prevents bone loss, helping to reduce the risk of fractures due to osteoporosis.
Dosage and Administration:
- Recommended Dose: 1 mg daily, taken orally. Dosage may be adjusted based on individual response and treatment goals.
- Administration: Take with or without food, preferably at the same time each day, as part of a hormone replacement therapy regimen.
- Duration: The duration of therapy depends on the patient’s response and clinical needs.
Side Effects:
- Common: Nausea, headache, breast tenderness, weight gain, and bloating.
- Serious: Increased risk of blood clots, stroke, heart disease, and endometrial cancer, especially in women with a history of these conditions.
- Long-Term: Potential risks of breast cancer, liver disease, and gallbladder issues.
Precautions:
Progynova should be used with caution in women with a history of breast cancer, liver disease, or blood clotting disorders. Regular monitoring of liver function, blood pressure, and bone density is recommended during long-term use. Pregnancy and breastfeeding are contraindications.
Storage:
Store at room temperature (15°C to 30°C) in a dry place, away from light. Keep out of reach of children.
Conclusion:
Progynova 1 mg is an effective option for managing menopausal symptoms and preventing osteoporosis in postmenopausal women. It should be used with caution and under the guidance of a healthcare provider due to potential risks such as blood clots and hormone-sensitive cancers. Regular medical monitoring is recommended for optimal management.
Fibrodone Pirfenidone 801 mg Tablet
Product Brochure
| Strength | 801 mg |
| Packaging Size | 10X10 Tablets |
| Brand | Fibrodone |
| Manufactured By | Lupin Ltd |
| Composition | Pirfenidone 801 mg |
| Treatment | Idiopathic Pulmonary Fibrosis |
Fibrodone (Pirfenidone) 801 mg Tablet
OverviewFibrodone is a brand name for pirfenidone, a medication used to treat idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by the scarring of lung tissue.
Indications- Idiopathic Pulmonary Fibrosis (IPF): Primarily indicated for slowing the progression of IPF and improving lung function.
Pirfenidone has anti-fibrotic and anti-inflammatory properties. It works by inhibiting the synthesis of proteins that contribute to fibrosis (scarring) in the lungs, thus helping to preserve lung function.
Dosage and Administration- Typical Dosage: The usual starting dose is 801 mg taken three times daily (total of 2403 mg per day), with food to help minimize gastrointestinal side effects.
- Administration: Swallow the tablet whole; do not crush or chew.
- Common Side Effects:
- Nausea
- Diarrhea
- Fatigue
- Rash
- Serious Side Effects:
- Liver enzyme elevations
- Allergic reactions
- Risk of pulmonary complications
- Hypersensitivity to pirfenidone or any of its components.
- Regular monitoring of liver function tests is recommended due to the risk of liver problems.
- Patients should be monitored for signs of severe skin reactions and pulmonary complications.
- Store at room temperature, away from moisture and light.
- Advise patients to take the medication with food to reduce the risk of gastrointestinal discomfort.
- Encourage reporting of any unusual side effects, particularly signs of liver issues (e.g., jaundice, severe fatigue).
Fibrodone (pirfenidone) is an essential treatment for managing idiopathic pulmonary fibrosis. Adhering to the prescribed dosage and maintaining regular follow-ups can help manage the condition effectively. Always consult a healthcare provider for personalized medical advice.
Mylan Avonza Tablet
Product Brochure
| Dose/Strength | 300mg/300mg/400mg |
| Pack Size | 1x30Tablets |
| Salt Composition | Lamivudine (300mg) + Tenofovir disoproxil fumarate (300mg) + Efavirenz (400mg) |
| Brand Name | Avonza |
| Marketer | Mylan Pharmaceuticals Pvt Ltd - A Viatris Company |
| Treatment | HIV infection |
Overview
Mylan Avonza is a combination medication used primarily for the treatment of infections caused by specific bacteria and parasites. The active ingredients typically include azithromycin and ornidazole, which work together to combat a variety of infections.
- Bacterial Infections: Effective against respiratory, skin, and soft tissue infections caused by susceptible bacteria.
- Parasitic Infections: Used for treating certain parasitic infections, such as those caused by protozoa.
- Azithromycin: A macrolide antibiotic that works by inhibiting bacterial protein synthesis, thereby preventing bacterial growth.
- Ornidazole: An antiprotozoal and antibacterial agent that disrupts the DNA of the microorganisms, effectively killing them.
- Dosage: The recommended dosage and duration of treatment depend on the specific infection being treated and the patient's age and health condition.
- Administration: Mylan Avonza tablets should be taken orally with or without food. It is essential to follow the prescribed regimen for the best therapeutic outcome.
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Fatigue
- Allergic reactions (e.g., rash, itching, swelling)
- Severe gastrointestinal disturbances
- Liver function abnormalities
- Monitor for signs of allergic reactions and gastrointestinal issues.
- Regular liver function tests may be necessary in prolonged treatments.
Mylan Avonza should not be used in:
- Patients with known hypersensitivity to azithromycin, ornidazole, or any components of the formulation.
- Individuals with a history of liver dysfunction.
Inform your healthcare provider about all medications, supplements, and herbal products being taken, as Mylan Avonza may interact with:
- Other antibiotics or antifungal medications.
- Medications that affect liver enzymes.
Store Mylan Avonza tablets at room temperature, away from moisture and heat, and keep out of reach of children.
Patient Counseling Information- Educate patients about the importance of completing the full course of the medication, even if symptoms improve before finishing the treatment.
- Discuss potential side effects and the importance of reporting any unusual symptoms, especially signs of an allergic reaction.
- Advise on the importance of following a healthcare provider's guidance regarding dosage and administration.
Mylan Avonza tablets are an effective treatment option for various bacterial and parasitic infections. With adherence to the prescribed regimen and appropriate monitoring, Mylan Avonza can significantly improve patient outcomes. Always consult a healthcare provider for personalized medical advice and treatment plans.
Ulitas 5mg Tablet
Product Brochure
| Strength | 5 mg |
| Packaging Size | 10 Tablet in 1 Strip |
| Composition | Ulipristal acetate 5 mg |
| Brand | Ulitas |
| Manufacturer | Intas Pharmaceuticals Ltd |
| Treatment | Uterine fibroids |
Overview
Ulitas is a medication containing the active ingredient losartan, which is primarily used to treat high blood pressure (hypertension) and certain conditions related to heart health.
- Hypertension: Used to lower blood pressure in adults and children over the age of 6.
- Heart Failure: May be prescribed to help manage heart failure and reduce the risk of hospitalization.
- Diabetic Nephropathy: Indicated for the treatment of kidney disease in patients with type 2 diabetes and hypertension.
Losartan works by:
- Blocking Angiotensin II Receptors: It inhibits the effects of angiotensin II, a hormone that causes blood vessels to constrict. By blocking these receptors, losartan helps relax and widen blood vessels, leading to lower blood pressure.
- Dosage: The typical starting dose for adults is 50 mg once daily, which may be adjusted based on blood pressure response. The maximum recommended dose is usually 100 mg daily.
- Administration: Ulitas can be taken with or without food. It's important to take it at the same time each day for consistent blood pressure management.
Common side effects may include:
- Dizziness or lightheadedness
- Fatigue
- Nasal congestion
- Elevated potassium levels (hyperkalemia)
- Renal Function: Monitor kidney function, particularly in patients with existing kidney issues or those taking other medications affecting the kidneys.
- Pregnancy: Not recommended during pregnancy, especially in the second and third trimesters, as it can harm the fetus.
- Angioedema: Rarely, losartan can cause swelling of the face, lips, or throat. Patients should seek immediate medical attention if this occurs.
- Hypersensitivity: Known allergies to losartan or any components of the formulation.
- Pregnancy: Should not be used in pregnant women.
- Losartan may interact with other medications, particularly those that increase potassium levels or affect renal function. Always inform your healthcare provider of all medications and supplements being taken.
- Store Ulitas at room temperature, away from moisture and light. Keep out of reach of children.
- Educate patients on the importance of adherence to the prescribed dosage and monitoring blood pressure regularly.
- Advise them to report any unusual symptoms, especially signs of allergic reactions or significant changes in blood pressure.
- Discuss lifestyle modifications, such as diet and exercise, that can help improve overall blood pressure control.
Ulitas (5 mg Tablet) is an effective treatment option for managing hypertension and related conditions. Proper monitoring, patient education, and adherence to the treatment regimen are essential for optimal outcomes. Always consult a healthcare provider for personalized advice and guidance.
Truvada 200 mg 245 mg Tablet
Product Brochure
| Dose/Strength | 200mg/245mg |
| Composition | Emtricitabine/Tenofovir Disoproxil 200 mg / 245 mg tablet |
| Strength | Truvada 200 mg/245 Mg |
| Brand Name | Truvada |
| Manufacturer By | Gilead Sciences Ltd |
| Treatment | HIV infection |
Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) 200 mg/245 mg Tablet
Overview: Truvada is a fixed-dose combination medication that contains emtricitabine and tenofovir disoproxil fumarate, used for the treatment of HIV-1 infection and for pre-exposure prophylaxis (PrEP) to reduce the risk of acquiring HIV in high-risk individuals.
Indications:
- HIV Infection: For the treatment of HIV-1 infection in adults and pediatric patients as part of a comprehensive antiretroviral regimen.
- PrEP: For use in high-risk individuals to prevent HIV infection.
Mechanism of Action:
- Emtricitabine: A nucleoside reverse transcriptase inhibitor (NRTI) that inhibits reverse transcriptase, blocking the conversion of viral RNA into DNA.
- Tenofovir Disoproxil Fumarate: Another NRTI that also inhibits reverse transcriptase, further reducing viral replication.
Dosage and Administration:
- Recommended Dose: For HIV treatment, typically one tablet taken orally once daily. For PrEP, the same dosage applies.
- Administration: Can be taken with or without food. Consistency in timing is important for effectiveness.
Side Effects: Common side effects may include:
- Nausea
- Diarrhea
- Fatigue
- Headache
- Possible changes in kidney function
- Bone density loss (with long-term use)
Warnings and Precautions:
- Renal Function: Regular monitoring of kidney function is recommended, especially in patients with pre-existing kidney issues.
- Liver Function: Monitor liver function, particularly in patients with hepatitis B or liver disease.
- Bone Health: Long-term use may impact bone mineral density; regular assessments are advised.
Contraindications:
- Hypersensitivity to emtricitabine, tenofovir, or any components of the formulation.
- Not recommended for individuals with active hepatitis B virus infection without appropriate monitoring.
Drug Interactions: Truvada may interact with other medications, particularly those that affect kidney function or are metabolized by the liver. Patients should inform their healthcare provider about all medications and supplements being taken.
Storage Instructions: Store at room temperature, away from moisture and light. Keep out of reach of children.
Patient Counseling Information:
- Advise patients to take the medication as prescribed and not to miss doses to maintain effective viral suppression or preventive measures.
- Discuss the importance of regular follow-up appointments for monitoring kidney function, liver function, and overall health.
- Instruct patients to report any unusual side effects, particularly related to kidney function or signs of liver problems.
Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) 200 mg/245 mg Tablets are an effective treatment option for HIV-1 infection and for pre-exposure prophylaxis. Proper adherence to dosing, monitoring for side effects, and patient education are vital for optimizing treatment outcomes. Always consult a healthcare provider for personalized treatment recommendations.
250mg Abiraterone Acetate Tablet
Product Brochure
| Strength | 250 mg |
| Form | Tablet |
| Packaging Size | 120 Tablets |
| Brand | Oncocare |
| Shelf Life | 24 Months |
| Medicine brand | Ariteron |
| Medicine form | Tablets |
| Medicine name | Abiraterone acetate tablets |
| Medicine strength | 250 mg |
| Packaging size | 120 tablets |
Tafero EM Emtricitabine Tenofovir Alafenamide Tablet
Product Brochure
| Composition | Emtricitabine 200mg And Tenofovir Alafenamide 25mg |
| Packaging Size | 30 Tablet |
| Brand | Tafero EM |
| Pack Type | Box |
| Product Strength | 225mg |
500mg Mycophenolate Mofetil Tablet
Product Brochure
| Strength | 500 mg |
| Packaging size | 6*10 Tablets |
| Packaging Type | Box |
| Brand | Mycept |
| Shelf life | 24 Months |
| Usage/Application | to treat people with lupus |
| Manufactured by | Panacea biotec |
| Medicine brand | Mycept-500 |
| Medicine form | Tablet |
| Medicine name | Mycophenolate mofetil tablets ip |
| Medicine strength | 500 mg |
| Packaging size | 6ร10 |
100mg Clomifene Tablet
Product Brochure
| Strength | 100 mg |
| Packaging Size | 10 x 10 |
| Dose Strength | 100 mg |
| Product Type | Finished Product |
| Packaging Type | Box |
| Form | Tablet |
| Brand | Sunrise |
| Medicine brand | Clofi-100 |
| Medicine form | Tablet |
| Medicine name | clomifene tablets ip |
| Medicine strength | 100 mg |
| Packaging size | 10 x 10 |
| Packaging type | Strip |
| Salt composition | Clomifene |
1mg Anaday Anastrozole Tablet
Product Brochure
| Strength | 1 mg |
| Form | Tablet |
| Packaging Size | 1*10 Tablets |
| Brand | Zuventus |
| Shelf Life | 2 Years |
| Usage | Used To Treat Breast Cancer |
| Composition | Anastrozole |
Anaday 1mg Tablet (Anastrozole)
Overview:
Anaday (Anastrozole) is a non-steroidal aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It works by inhibiting the enzyme aromatase, which is responsible for the conversion of androgens to estrogens in the body. By lowering estrogen levels, Anaday helps to slow or stop the growth of certain types of breast cancer that require estrogen to grow.
Indications:
Anaday 1mg Tablet is indicated for:
- Breast Cancer: Used as adjuvant therapy in postmenopausal women with estrogen receptor-positive (ER+) early breast cancer.
- Metastatic Breast Cancer: For the treatment of postmenopausal women with hormone receptor-positive breast cancer that has spread to other parts of the body.
- Prevention: In some cases, Anaday may be used to reduce the risk of breast cancer recurrence in high-risk postmenopausal women.
Mechanism of Action:
Anastrozole inhibits aromatase, the enzyme responsible for converting androgens to estrogens. Estrogen is known to promote the growth of some types of breast cancer cells. By blocking estrogen production, Anaday reduces estrogen levels in the body, thereby slowing or halting the growth of estrogen-dependent tumors.
Dosage and Administration:
- Recommended Dose: The usual dose is 1 mg taken orally once a day. The dosage is typically maintained during the entire course of therapy.
- Administration: Anaday should be taken by mouth with or without food. It is important to follow the prescribed dosage and schedule recommended by your healthcare provider.
Side Effects:
Common side effects include:
- Hot flashes
- Joint pain
- Nausea
- Fatigue
- Headache Serious side effects may include:
- Bone thinning (osteoporosis)
- Heart problems (rare)
- Liver enzyme changes
- Increased risk of blood clots
Precautions:
- Bone Health: Patients may need bone density monitoring, as Anaday can lead to bone thinning.
- Pregnancy and Breastfeeding: Anaday should not be used during pregnancy or breastfeeding as it can harm the fetus or infant.
- Liver Impairment: Caution is advised in patients with liver problems, and liver function should be monitored.
Storage:
Store Anaday 1mg Tablet at room temperature (20°C to 25°C), away from moisture and heat.
Conclusion:
Anaday 1mg Tablet (Anastrozole) is an effective treatment for estrogen receptor-positive breast cancer in postmenopausal women. Regular monitoring for bone density and liver function is essential to ensure safe and effective use.
400mg Pazonat Pazopanib Tablet
Minimum Order Quantity: 10 Bottle
Product Brochure
| Dose/Strength | 400 mg |
| Form | Tablet |
| Brand | Natco |
| Pack Type | Box |
| Pack Size | 20 Tablets |
| Shelf Life | 2 Years |
| Usage | Used To Treat Kidney Cancer |
Pazonat 400 mg Tablet (Pazopanib)
Overview:Pazonat 400 mg Tablets contain Pazopanib, a tyrosine kinase inhibitor (TKI) that targets multiple receptors involved in tumor growth and blood vessel formation (angiogenesis). Pazopanib works by inhibiting vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor (PDGF) receptors, and c-kit, which are crucial for cancer cell proliferation and tumor vascularization. This helps to slow down the progression of various cancers, including renal cell carcinoma (RCC) and soft tissue sarcoma (STS).
Indications:Pazonat 400 mg Tablets are indicated for:
- Renal Cell Carcinoma (RCC): For the treatment of advanced or metastatic RCC in adults, either as a first-line therapy or for patients who have failed previous treatments.
- Soft Tissue Sarcoma (STS): For the treatment of advanced STS in adults after prior chemotherapy, excluding gastrointestinal stromal tumors (GISTs).
- Other Cancers: Pazopanib may also be used off-label for other cancers under the supervision of an oncologist.
Pazopanib works by inhibiting the action of several tyrosine kinases involved in the growth and spread of cancer. By blocking VEGF receptors, it impairs the formation of new blood vessels (angiogenesis) necessary for tumors to grow. Additionally, it targets PDGF receptors and c-kit, preventing cancer cells from dividing and spreading. This combination of effects reduces tumor size and prevents further cancer progression.
Dosage and Administration:- Recommended Dose: The usual dose of Pazonat 400 mg is one tablet daily, taken with or without food.
- Administration: Swallow the tablet whole with water. Do not chew or crush the tablet. It should be taken consistently at the same time each day to ensure effective treatment.
- Common Side Effects: Diarrhea, nausea, vomiting, fatigue, hypertension, liver enzyme elevation, and hair color changes.
- Serious Side Effects: Liver toxicity, heart problems (QT interval prolongation), hemorrhage, and blood clots. Regular monitoring of liver function, blood pressure, and heart rhythm is recommended during treatment.
- Liver Disease: Use with caution in patients with liver impairment, as Pazopanib can cause liver toxicity.
- Heart and Blood Pressure Monitoring: Pazopanib can affect heart function and cause hypertension. Regular monitoring of blood pressure and heart health is necessary.
- Pregnancy and Lactation: Pazopanib is not recommended during pregnancy due to potential harm to the fetus. It is also excreted in breast milk, so breastfeeding should be avoided during treatment.
Store Pazonat 400 mg Tablets at room temperature (15°C to 30°C), away from light, moisture, and out of the reach of children.
Conclusion:Pazonat 400 mg Tablets (Pazopanib) are an effective treatment for advanced renal cell carcinoma and soft tissue sarcoma, as well as other cancers. While it can significantly slow tumor growth and improve survival, it is important to monitor for side effects, including liver toxicity and hypertension. Adherence to dosing schedules and regular medical check-ups are essential for optimal therapy.
Tranexaheal MF Tranexamic Mefenamic Acid Tablet
Product Brochure
| Dose/Strength | 500 mg/250 mg |
| Pack Size | 10 x 10 Tablets |
| Salt Composition | Tranexamic Mefenamic |
| Brand Name | Tranexaheal |
| Manufactured By | Healing Pharma |
| Treatment | Prevent Excessive Blood Loss menstrual period |
Overview: Tranexaheal MF combines Tranexamic Acid (an antifibrinolytic agent) and Mefenamic Acid (a nonsteroidal anti-inflammatory drug, NSAID). This combination is used primarily to manage heavy menstrual bleeding (menorrhagia) and to reduce pain and inflammation associated with menstrual disorders. Tranexamic Acid helps prevent the breakdown of blood clots, while Mefenamic Acid reduces pain and inflammation.
Indications: Tranexaheal MF Tablet is indicated for:
- Menorrhagia (heavy menstrual bleeding): To reduce bleeding and discomfort during menstruation.
- Pain and inflammation associated with menstrual disorders, such as dysmenorrhea (painful periods).
Mechanism of Action:
- Tranexamic Acid works by inhibiting plasminogen activation, preventing the breakdown of fibrin, and stabilizing blood clots. This reduces excessive bleeding, especially during menstruation.
- Mefenamic Acid is an NSAID that inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins, chemicals that mediate pain, inflammation, and fever.
The combined action of Tranexamic Acid and Mefenamic Acid makes this tablet effective for managing both bleeding and associated pain in menstrual disorders.
Dosage and Administration:
- For menorrhagia or heavy menstrual bleeding, the recommended dose is typically 1 tablet 2-3 times daily starting from the first day of menstruation, usually for up to 5 days.
- For dysmenorrhea or painful periods, the usual dose is 1 tablet every 8 hours, depending on the severity of symptoms.
Always take with food to minimize gastrointestinal irritation.
Side Effects: Common side effects include:
- Gastrointestinal symptoms: Nausea, abdominal discomfort, or diarrhea.
- Headache, dizziness, or tiredness.
- Skin rash or allergic reactions.
Serious side effects may include:
- Severe gastrointestinal bleeding (due to NSAID component).
- Blood clotting disorders (especially if used improperly).
- Kidney or liver issues in prolonged use.
Precautions:
- Gastrointestinal Issues: Use with caution in patients with a history of peptic ulcers, gastritis, or GI bleeding.
- Kidney or Liver Disease: Caution in patients with existing kidney or liver impairment.
- Pregnancy/Breastfeeding: Not recommended during pregnancy, especially in the third trimester. Consult a doctor before use during breastfeeding.
- Blood Clotting: Caution in patients with conditions that predispose to thrombosis (blood clots).
Storage: Store at room temperature (20°C to 25°C), away from moisture and light. Keep out of reach of children.
Conclusion: Tranexaheal MF (Tranexamic Acid + Mefenamic Acid) Tablet is a combined treatment for managing heavy menstrual bleeding and pain during menstruation. It helps to control bleeding and reduce associated pain, improving the quality of life for women with menstrual disorders. Proper usage and monitoring for side effects are important for safety.
Healpecia 1 Finasteride Tablet
Product Brochure
| Strength | 1 mg |
| Usage/Application | Clinical Use |
| Packaging Type | Box |
| Brand | Healing Pharma |
| Shelf Life | 24 Months |
| Product Packaging Size | 30x10 Tablets |
| Medicine brand | Healpecia-1 |
| Medicine form | Tablets |
| Medicine name | Finasteride tablets |
| Medicine strength | 1mg |
| Packaging size | 10 tablets |
| Packaging type | Box |
| Salt composition | Finasteride tablets ip 1mg |
Diane-35 Cyproterone Ethinyl Estradiol Tablet
Product Brochure
| Pack Size | 21 Tablets |
| Strength | 2 mg / 35 mcg |
| Pack Type | Box |
| Usage/Application | Treatment Of Moderate To Severe Acne |
| Form Of Medicines | Tablet |
| Brand | Bayer |
| Shelf Life | 5 Years |
4mg Barijak Baricitinib Tablet
Product Brochure
| Strength / Dose | 4 mg |
| Packaging Size | 14 Tablets |
| Usage | For Covid Treatment |
| Pack Type | Box |
| Form | Tablet |
| Brand Name | Natco |
| Shelf Life | 2 Years |
Overview:
4mg Barijak (Baricitinib) Tablet contains Baricitinib, a Janus kinase (JAK) inhibitor used to treat moderate to severe rheumatoid arthritis and other inflammatory conditions. Baricitinib works by selectively inhibiting JAK1 and JAK2 enzymes, which are involved in the signaling pathways of various cytokines and growth factors. This inhibition helps reduce inflammation, pain, and damage in conditions like rheumatoid arthritis.
Indications:
4mg Barijak (Baricitinib) Tablet is indicated for:
- Rheumatoid Arthritis (RA): For adults with moderate to severe RA who have had an inadequate response to or are intolerant of methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
- Atopic Dermatitis: Approved for moderate to severe cases in adults and children 12 years or older (in some regions).
- COVID-19: In some cases, used for severe or critical COVID-19 in patients requiring oxygen support.
Mechanism of Action:
Baricitinib selectively inhibits JAK1 and JAK2 enzymes, which play a crucial role in the signaling of pro-inflammatory cytokines and immune responses. By blocking these enzymes, Baricitinib reduces the activity of immune cells involved in the inflammatory process, thereby controlling symptoms and slowing disease progression.
Dosage and Administration:
- Rheumatoid Arthritis: 4 mg once daily, with or without food. The dose can be reduced to 2 mg daily based on tolerance and the presence of side effects.
- Atopic Dermatitis: 2 mg to 4 mg once daily, depending on the severity of the condition.
- COVID-19: Follow the specific guidelines and dosing recommendations based on clinical status (typically initiated in hospitalized patients).
Side Effects:
Common side effects include:
- Upper respiratory tract infections, headache, and nausea.
- Diarrhea, acne, and high blood pressure.
Serious side effects may include:
- Increased risk of infections (e.g., tuberculosis, bacterial, fungal infections).
- Blood clots, heart problems, and liver enzyme elevations.
- Cancer risk: Possible increased risk of certain cancers with long-term use.
Precautions:
- Infection risk: Screen for tuberculosis and other infections before starting treatment.
- Liver and kidney function: Monitor liver enzymes and renal function during treatment.
- Pregnancy: Baricitinib is contraindicated during pregnancy due to potential harm to the fetus.
Storage:
Store at room temperature (20°C–25°C) in a tightly closed container, away from moisture and light.
Conclusion:
4mg Barijak (Baricitinib) Tablet is an effective treatment for rheumatoid arthritis and certain inflammatory conditions, improving symptoms and slowing disease progression. Regular monitoring for infections, blood counts, and organ function is essential to ensure safe use.
Selepeg Selexipag 200mcg Tablets
Product Brochure
| Strength | 200 mcg |
| Packaging Size | 1*10 Tablets in 1 Box |
| Composition | Selexipag 200 mcg |
| Brand | Selepag |
| Manufacturer | MSN Laboratories |
| Treatment | Pulmonary Arterial Hypertension (PAH) |
Selepeg (Selexipag) 200 mcg Tablets
OverviewSelepeg contains selexipag, a medication used primarily for the treatment of pulmonary arterial hypertension (PAH). It functions as a selective agonist of the prostacyclin receptor, helping to dilate blood vessels and reduce blood pressure in the pulmonary arteries.
Indications- Pulmonary Arterial Hypertension (PAH): Indicated for the treatment of adults with PAH to delay disease progression and reduce the risk of hospitalization due to PAH-related complications.
Selexipag mimics the action of prostacyclin, a naturally occurring substance that helps to relax and widen blood vessels. By activating the prostacyclin receptor, selexipag improves blood flow and reduces pulmonary artery pressure.
Dosage and Administration- Typical Dosage: The recommended starting dose is usually 200 mcg taken orally twice daily. The dose may be titrated based on the patient's response and tolerability, with a maximum dose typically not exceeding 1600 mcg per day.
- Administration: Tablets should be taken consistently, either with or without food. Swallow the tablets whole; do not crush or chew.
- Common Side Effects:
- Headache
- Diarrhea
- Nausea
- Jaw pain
- Flushing
- Serious Side Effects:
- Severe hypotension (low blood pressure)
- Increased risk of bleeding (due to effects on platelets)
- Liver enzyme elevation
- Hypersensitivity to selexipag or any component of the formulation.
- Severe hepatic impairment.
- Monitor blood pressure regularly due to the risk of hypotension.
- Liver function tests may be necessary to monitor for hepatic impairment.
- Store at room temperature (20°C to 25°C / 68°F to 77°F) in a dry place, away from light.
- Educate patients about potential side effects, particularly headache and gastrointestinal symptoms, and advise them to report any severe reactions.
- Discuss the importance of adhering to the prescribed dosage and the need for regular follow-up appointments.
Selepeg (selexipag) is an effective treatment option for pulmonary arterial hypertension, helping to improve patient outcomes by enhancing blood flow and reducing pressure in the lungs. Proper administration and monitoring are crucial for maximizing therapeutic benefits. Always consult a healthcare provider for personalized medical advice.
200mcg Uptravi Selexipag Tablets
Product Brochure
| Strength | 200 mcg |
| Packaging Size | 140 Tablets |
| Packaging Type | Box |
| Brand | Actelion |
| Shelf life | 24 Months |
| Usage | Used In Treatment Of Pulmonary Arterial Hypertension |
| Form | Tablet |
Uptravi (Selexipag 200mcg Tablets)
Overview:
Uptravi 200mcg Tablet contains Selexipag, a selective prostacyclin IP receptor agonist used primarily in the treatment of pulmonary arterial hypertension (PAH). PAH is a condition characterized by elevated blood pressure in the arteries of the lungs, which can lead to heart failure and reduced exercise capacity. Selexipag works by activating the prostacyclin receptor, resulting in vasodilation of pulmonary arteries, reducing pulmonary vascular resistance, and improving blood flow. This helps alleviate symptoms and improves overall exercise capacity in patients with PAH.
Indications:
Uptravi 200mcg Tablets are indicated for:
- Pulmonary Arterial Hypertension (PAH): To delay disease progression and improve exercise capacity in patients with PAH, either as monotherapy or in combination with other PAH treatments.
Mechanism of Action:
Selexipag is a prostacyclin IP receptor agonist. By binding to the prostacyclin receptor on smooth muscle cells in the pulmonary vasculature, Selexipag mimics the action of natural prostacyclin. This results in vasodilation, reduced pulmonary vascular resistance, and improvement in symptoms of PAH. It also inhibits platelet aggregation and reduces inflammation, contributing to overall cardiovascular health.
Dosage and Administration:
- Pulmonary Arterial Hypertension (PAH):
The starting dose is 200mcg twice daily.
The dose may be gradually increased by 200mcg every week as tolerated, up to a maximum of 1,600mcg twice daily. - Administration: Take tablets with or without food. Swallow the tablets whole with a glass of water. Do not chew or crush the tablets.
Side Effects:
Common side effects include:
- Headache, nausea, diarrhea, and jaw pain.
- Flushing, muscle pain, and fatigue. Serious side effects may include:
- Liver toxicity: Liver function tests should be monitored regularly.
- Hypotension and arrhythmias: Particularly when starting or increasing the dose.
- Bleeding risk: Selexipag may increase the risk of bleeding, especially in patients with a history of bleeding disorders.
Precautions:
- Liver Function: Monitor liver enzymes regularly due to the risk of hepatotoxicity.
- Renal Impairment: Use with caution in patients with moderate renal impairment.
- Bleeding Risks: Selexipag should be used with caution in patients at risk for bleeding.
- Pregnancy and Breastfeeding: Selexipag is contraindicated during pregnancy and breastfeeding due to potential risks to the fetus and infant.
- Dose Titration: Selexipag should be titrated carefully to minimize side effects during the initiation and dose escalation phases.
Storage:
Store Uptravi 200mcg Tablets at room temperature (20°C to 25°C), away from moisture and light. Keep out of reach of children.
Conclusion:
Uptravi (Selexipag 200mcg Tablets) is a valuable treatment for pulmonary arterial hypertension (PAH). It works by activating the prostacyclin receptor to reduce pulmonary vascular resistance and improve exercise capacity. Regular monitoring for liver function, bleeding risks, and proper dose titration are crucial for safe and effective treatment.
HepaMerz L-Ornithine-L-Aspartate Tablet
Product Brochure
| Strength | 150 mg |
| Pack Size | 1*10 Tablets |
| Brand Name | Hepamerz |
| Manufacturer | Win-Medicare Pvt Ltd |
| Composition | L-Ornithine L-Aspartate 150 mg + Pancreatin 100 mg |
| Treatment | Indigestion |
HepaMerz (L-Ornithine-L-Aspartate) Tablets
OverviewHepaMerz contains L-ornithine-L-aspartate, an amino acid compound used primarily to support liver function and treat conditions related to liver dysfunction, such as hepatic encephalopathy.
Indications- Hepatic Encephalopathy: Used to reduce the severity and frequency of episodes in patients with liver disease.
- Liver Support: May be used as a supportive treatment in various liver conditions to help improve liver metabolism and function.
L-ornithine-L-aspartate is involved in the urea cycle, helping to detoxify ammonia in the liver. By reducing ammonia levels in the blood, it may help alleviate symptoms associated with liver dysfunction and improve overall liver health.
Dosage and Administration- Typical Dosage: The usual dosage may vary based on the condition being treated. Commonly, it is taken in divided doses, often ranging from 3 to 6 tablets per day.
- Administration: Tablets should be taken orally with water. It's advisable to follow specific dosing instructions provided by a healthcare provider.
- Common Side Effects:
- Gastrointestinal disturbances (nausea, diarrhea)
- Abdominal pain
- Allergic reactions (rare)
- Hypersensitivity to L-ornithine, L-aspartate, or any components of the formulation.
- Patients with certain metabolic disorders should use caution.
- Monitor liver function regularly in patients with existing liver disease.
- Discuss with healthcare providers before using in patients with kidney impairment or metabolic disorders.
- Store at room temperature (20°C to 25°C / 68°F to 77°F) in a dry place, away from light.
- Educate patients on the importance of adhering to prescribed dosages and monitoring their symptoms.
- Advise them to report any unusual side effects or reactions during treatment.
HepaMerz (L-ornithine-L-aspartate) is beneficial for supporting liver health and managing hepatic encephalopathy. Proper administration and monitoring are crucial for maximizing therapeutic benefits. Always consult a healthcare provider for personalized medical advice.
80mg Febuza Febuxostat Tablet
Product Brochure
| Strength | 80mg |
| Brand | Sunrise |
| Packaging Size | 10*10 Tablets |
| Packaging Type | Box |
| Composition | Febuxostat 20mg |
| Shelf Life | 24 Months |
| Usage | Rheumatoid Arthritis, Osteoarthritis Arthritis, Gout Attack |
| Form | Tablet |
Overview:
80mg Febuza Tablet contains Febuxostat, a xanthine oxidase inhibitor used to treat gout and hyperuricemia (elevated levels of uric acid in the blood). Febuxostat works by inhibiting the enzyme xanthine oxidase, which is responsible for the production of uric acid. By reducing uric acid production, Febuxostat helps prevent gout attacks and the formation of uric acid crystals in joints.
Indications:
Febuza 80mg Tablet is indicated for:
- Gout: Chronic management of hyperuricemia to prevent gout attacks.
- Hyperuricemia: Treatment of elevated uric acid levels in patients with conditions such as gout or tumor lysis syndrome (caused by chemotherapy).
Mechanism of Action:
Febuxostat selectively inhibits xanthine oxidase, an enzyme involved in the conversion of hypoxanthine to xanthine and xanthine to uric acid. By blocking this enzyme, Febuxostat reduces the production of uric acid, helping to lower serum uric acid levels and prevent the accumulation of uric acid crystals in joints and tissues, thus reducing the frequency of gout attacks.
Dosage and Administration:
- Gout and Hyperuricemia: The usual starting dose is 40 mg once daily. The dose may be increased to 80 mg once daily depending on the serum uric acid level and patient response.
- Treatment should be adjusted based on uric acid levels, with a target of maintaining serum uric acid below 6 mg/dL.
Febuza should be taken once daily, with or without food. Drink plenty of fluids to prevent the formation of uric acid crystals in the urine.
Side Effects:
Common side effects include:
- Liver enzyme elevation, nausea, and diarrhea.
- Rash, headache, and arthralgia (joint pain).
Serious side effects may include:
- Hepatotoxicity: Liver damage or liver failure.
- Cardiovascular effects: Increased risk of heart-related issues, including heart attack or stroke.
- Severe allergic reactions: Rash, swelling, or difficulty breathing.
Precautions:
- Liver function: Monitor liver enzymes periodically during treatment, especially in patients with preexisting liver conditions.
- Cardiovascular risks: Use with caution in patients with a history of heart disease or stroke.
- Pregnancy: Febuxostat is not recommended during pregnancy unless the benefits outweigh the risks.
Storage:
Store at room temperature (20°C–25°C) in a tightly closed container, away from light and moisture.
Conclusion:
80mg Febuza (Febuxostat) Tablet is an effective treatment for managing gout and hyperuricemia by reducing uric acid production. Regular monitoring of liver function and uric acid levels is essential for optimizing treatment and preventing side effects.
Ursodec-300 Ursodeoxycholic Acid Tablet
Product Brochure
| Strength | 300 mg |
| Packaging Size | 1*10 Tablets |
| Packaging Type | Box |
| Brand | Healing Pharma |
| Shelf life | 24 Months |
| Usuage | To Treat primary biliary cholangitis |
| Form | Tablet |
Overview:
Ursodec-300 Tablet contains Ursodeoxycholic acid (UDCA), a naturally occurring bile acid that helps in the treatment of liver diseases. It works by decreasing the levels of cholesterol in bile and by promoting the dissolution of cholesterol gallstones. Ursodeoxycholic acid is used to treat primary biliary cirrhosis (PBC), gallstones, and certain other liver conditions, improving liver function and reducing symptoms related to biliary stasis.
Indications:
Ursodec-300 Tablet is indicated for:
- Primary Biliary Cirrhosis (PBC): To slow disease progression and improve liver function.
- Gallstones: Treatment of cholesterol gallstones in patients who are not candidates for surgery.
- Chronic liver diseases: Including non-alcoholic fatty liver disease (NAFLD) and hepatic fibrosis.
- Intrahepatic Cholestasis of Pregnancy: To reduce bile acid accumulation during pregnancy.
Mechanism of Action:
Ursodeoxycholic acid works by replacing more toxic bile acids in the liver and bile. It reduces cholesterol secretion, preventing the formation of cholesterol crystals and gallstones. It also improves bile flow, protects liver cells from bile acid toxicity, and reduces liver enzyme levels in diseases like PBC.
Dosage and Administration:
- Primary Biliary Cirrhosis (PBC): Typically, 300 mg to 600 mg daily, divided into 2 or 3 doses, based on the patient's response.
- Gallstones: 8-10 mg/kg/day, usually for a period of 6 to 24 months.
- Other liver conditions: Dosing is based on the specific condition and severity.
Tablets should be taken with food to enhance absorption.
Side Effects:
Common side effects include:
- Gastrointestinal symptoms: Diarrhea, nausea, indigestion.
- Headache and dizziness.
Serious side effects may include:
- Liver enzyme abnormalities: Hepatitis or worsening liver function in some cases.
- Allergic reactions: Rash, itching, or swelling.
- Acute pancreatitis: Rare but possible.
Precautions:
- Liver function: Regular monitoring of liver enzymes is recommended, especially during the early stages of therapy.
- Pregnancy: Ursodeoxycholic acid should be used during pregnancy only if the potential benefits outweigh the risks.
- Gallbladder function: Not recommended in patients with gallbladder calcification or severe gallbladder dysfunction.
Storage:
Store at room temperature (20°C–25°C), in a tightly closed container. Protect from moisture and light.
Conclusion:
Ursodec-300 (Ursodeoxycholic Acid) Tablet is a vital treatment for improving liver function and managing conditions like PBC and gallstones. Monitoring liver function and gastrointestinal side effects is essential for safe use.
Lamivudine & Zidovudine Tablets ( Douvir Tablets)
Product Brochure
| Pack Size | 60 Tablets in 1 Bottle |
| Brand Name | Douvir |
| Manufacturer By | Cipla Ltd |
| Treatment | Ongoing Hepatitis B Infection (HBV) Contamination |
| Strength | 150mg/300mg |
| Salt Composition | Lamivudine 150mg & Zidovudine 300mg |
Douvir Tablets (Lamivudine & Zidovudine)
Overview: Douvir is a combination antiretroviral medication that contains lamivudine and zidovudine, used in the treatment of HIV-1 infection. This combination helps to suppress viral replication and improve immune function.
Indications:
- HIV Infection: Indicated for the treatment of HIV-1 infection in adults and pediatric patients as part of a comprehensive antiretroviral therapy regimen.
Mechanism of Action:
- Lamivudine: A nucleoside reverse transcriptase inhibitor (NRTI) that inhibits reverse transcriptase, preventing the conversion of viral RNA into DNA.
- Zidovudine: Another NRTI that also inhibits reverse transcriptase and blocks viral replication.
Dosage and Administration:
- Recommended Dose: The typical dosage is usually one tablet taken orally twice daily, but specific recommendations may vary based on individual patient needs.
- Administration: Can be taken with or without food. It’s important to maintain consistency in timing for optimal effectiveness.
Side Effects: Common side effects may include:
- Nausea
- Fatigue
- Headache
- Dizziness
- Anemia (low red blood cell count)
- Neutropenia (low white blood cell count)
Warnings and Precautions:
- Hematologic Toxicity: Monitor blood counts regularly, as both lamivudine and zidovudine can cause bone marrow suppression.
- Liver Function: Regular monitoring of liver function is recommended, particularly in patients with pre-existing liver conditions.
- Hypersensitivity Reactions: Be alert for signs of serious allergic reactions.
Contraindications:
- Hypersensitivity to lamivudine, zidovudine, or any components of the formulation.
- Use with caution in patients with a history of significant bone marrow suppression.
Drug Interactions: Douvir may interact with other medications, particularly those that also affect bone marrow function or are metabolized by the liver. Inform your healthcare provider about all medications being taken.
Storage Instructions: Store at room temperature, away from moisture and light. Keep out of reach of children.
Patient Counseling Information:
- Advise patients to take the medication as prescribed and not to miss doses, as adherence is crucial for viral suppression.
- Discuss the importance of regular follow-up appointments for monitoring blood counts and overall health.
- Instruct patients to report any unusual side effects, particularly signs of anemia or infection.
Douvir Tablets (Lamivudine & Zidovudine) are an important treatment option for managing HIV-1 infection. Proper dosing, monitoring for side effects, and patient education are essential for optimizing treatment outcomes. Always consult a healthcare provider for personalized treatment recommendations.
Rebagen 100 mg Tablets
Product Brochure
| Strength | 100 mg |
| Packaging Size | 10 Tablets in 1 Strip |
| Composition | Rebamipide 100 mg |
| Brand Name | Rebagen |
| Manufacturer | Macleods Pharmaceuticals Pvt Ltd |
| Treatment | Treatment of Mouth Ulcers |
Overview: Rebagen contains the active ingredient rebamipide, which is primarily used to treat gastrointestinal disorders. It is known for its protective effects on the gastric mucosa and its role in promoting healing.
Indications for UseRebagen is indicated for:
- Gastritis: Treatment of acute and chronic gastritis to reduce symptoms and promote healing of the gastric mucosa.
- Peptic Ulcers: Used as part of a therapeutic regimen for the healing of gastric and duodenal ulcers.
- Gastroesophageal Reflux Disease (GERD): Helps alleviate symptoms associated with acid reflux.
Rebamipide works by:
- Enhancing mucosal defense mechanisms in the stomach.
- Stimulating the production of mucus and bicarbonate, which protects the gastric lining.
- Promoting epithelial cell regeneration and repair in the gastrointestinal tract.
- Dosage: The typical dosage is 100 mg taken two to three times daily, depending on the specific condition being treated.
- Administration: The tablets should be taken orally with water, preferably before meals.
Common Side Effects:
- Nausea or vomiting
- Diarrhea
- Abdominal discomfort
Serious Side Effects:
- Allergic reactions (rare)
- Skin rashes or hives
- Use with caution in patients with a history of hypersensitivity to rebamipide or any of its components.
- Monitor for gastrointestinal symptoms, especially during the initial treatment phase.
- Consult a healthcare provider before use if pregnant, breastfeeding, or on other medications.
- Store at room temperature, away from moisture and heat.
- Keep out of reach of children.
Patients should be advised to:
- Follow the prescribed dosage and inform their healthcare provider if symptoms persist or worsen.
- Report any unusual symptoms or side effects, particularly gastrointestinal disturbances or allergic reactions.
- Maintain a balanced diet and avoid irritants like alcohol, caffeine, or spicy foods during treatment.
Rebagen 100 mg Tablets are an effective option for managing various gastrointestinal disorders, particularly those related to gastric mucosal protection and healing. Proper usage and monitoring are essential for achieving optimal therapeutic outcomes. Always consult a healthcare professional for personalized advice regarding its use.
150mg Canrib Olaparib Tablet
Product Brochure
| Dose/Strength | 150 mg |
| Form | Tablet |
| Usage/Application | Clinical |
| Brand | Adley |
| Packaging Type | Box |
| Packaging Size | 60 tablets |
Canrib Olaparib 150 mg Tablets
Overview:Canrib 150 mg Tablets contain Olaparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor used in the treatment of advanced ovarian cancer and other cancers with BRCA1/2 mutations. Olaparib works by blocking the PARP enzyme, which plays a critical role in repairing DNA damage in cells. In cancer cells, particularly those with defective BRCA genes, blocking PARP leads to accumulation of DNA damage, ultimately causing cancer cell death. Olaparib is used to treat patients with cancers that have specific genetic mutations, including ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer.
Indications:Canrib 150 mg Tablets are indicated for:
- Ovarian Cancer: In patients with BRCA-mutated ovarian cancer who have been previously treated with chemotherapy.
- Breast Cancer: For patients with BRCA1/2 mutations and metastatic breast cancer who have been treated with chemotherapy.
- Pancreatic Cancer: For patients with BRCA mutations and metastatic pancreatic cancer after chemotherapy.
- Prostate Cancer: For patients with BRCA mutations and metastatic castration-resistant prostate cancer.
Olaparib is a PARP inhibitor that works by inhibiting the PARP enzyme, which is essential for repairing single-strand DNA breaks. In normal cells, the repair mechanisms work to fix DNA damage, but in cancer cells with BRCA mutations, these repair pathways are already compromised. By inhibiting PARP, Olaparib causes accumulation of DNA damage in cancer cells, leading to cell death, while sparing normal healthy cells.
Dosage and Administration:- Recommended Dose: The typical dose of Canrib 150 mg is one tablet taken twice daily (total dose of 300 mg per day).
- Administration: The tablet should be swallowed whole with a glass of water and can be taken with or without food. It is important to take Canrib consistently at the same time each day to ensure maximum effectiveness.
- Common Side Effects: Nausea, fatigue, anemia, decreased appetite, vomiting, and diarrhea.
- Serious Side Effects: Myelodysplastic syndrome (MDS), acute leukemia, pneumonitis, and bone marrow suppression. Blood counts should be monitored regularly, especially during the initial treatment phase.
- Bone Marrow Suppression: Regular blood tests are required to monitor blood cell counts. Dose adjustments may be necessary if blood counts drop significantly.
- Liver Disease: Caution is advised in patients with liver dysfunction, as Olaparib is metabolized in the liver.
- Pregnancy and Lactation: Olaparib is contraindicated during pregnancy (Category D). Women of childbearing age should use effective contraception during treatment. Avoid breastfeeding during treatment with Canrib.
Store Canrib Olaparib 150 mg Tablets at room temperature (15°C to 30°C), away from light and moisture. Keep out of reach of children.
Conclusion:Canrib Olaparib 150 mg Tablets are an effective treatment for cancers with BRCA mutations, including ovarian, breast, pancreatic, and prostate cancers. By inhibiting PARP, Olaparib helps prevent cancer cells from repairing their DNA, leading to cancer cell death. Regular blood tests and monitoring for side effects such as bone marrow suppression are important for safe use.
Finrest-5 Finasteride Tablet
Product Brochure
| Packaging Size | 10*10 Tablets |
| Usage/Application | Clinical Use |
| Packaging Type | Box |
| Brand | Finrest |
| Form | Tablet |
| Shelf Life | 24 Months |
| Medicine form | Tablet |
| Medicine name | Finasteride tablets ip |
| Packaging size | 10 x 10 tablets |
| Packaging type | Box |
Febutop 80 Febuxostat Tablet
Product Brochure
| Strength | 80mg |
| Brand | Healing Pharma |
| Packaging Size | 3x10 Tablets |
| Packaging Type | Box |
| Usage | Osteoarthritis Arthritis |
| Medicine brand | Febutop |
| Medicine form | Tablets |
| Medicine name | Febuxostat tablets |
| Packaging size | 3x10 |
| Packaging type | Box |
| Salt composition | Febuxostat 80mg |
Rexigo Relugolix 120mg Tablets
Product Brochure
| Form | Tablet |
| Prescription/Non prescription | Prescription |
| Strength | 120mg |
| Pack Size | 3x10 Tab |
| Brand | Rexigo |
| Composition | Relugolix |
Rexigo 120mg Tablets (Relugolix)
Overview:
Rexigo (Relugolix) 120mg tablets are a prescription medication used to treat advanced prostate cancer and uterine fibroids. Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that works by lowering the production of sex hormones, particularly testosterone in men and estrogen in women. By inhibiting the GnRH receptor, it reduces the stimulation of the ovaries and testes, leading to reduced levels of sex hormones, which is beneficial in the treatment of hormone-sensitive conditions like prostate cancer and fibroids.
Indications:
Rexigo 120mg Tablets are primarily indicated for:
- Advanced Prostate Cancer: Used in the treatment of prostate cancer in men, either alone or in combination with other therapies.
- Uterine Fibroids: Used for the treatment of symptomatic uterine fibroids in women who are candidates for surgery.
Mechanism of Action:
Relugolix is a GnRH receptor antagonist that binds to and inhibits the GnRH receptor in the pituitary gland. This action decreases the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a significant reduction in the production of testosterone in men and estrogen in women. In prostate cancer, the reduction in testosterone slows tumor growth. In uterine fibroids, the decrease in estrogen reduces fibroid size and associated symptoms.
Dosage and Administration:
- Recommended Dose: The typical starting dose for prostate cancer is 120 mg once daily, while for uterine fibroids, it is also 120 mg daily.
- Administration: Rexigo should be taken orally once a day with or without food. Swallow the tablet whole with water.
- Missed Dose: If a dose is missed, take it as soon as possible, unless it is close to the time for the next dose.
Side Effects:
Common side effects include:
- Hot flashes, fatigue, headache, and muscle pain.
Serious side effects may include: - Cardiovascular issues: Increased risk of heart attack or stroke.
- Bone loss: Long-term use can lead to decreased bone mineral density.
- Liver function: Liver enzyme abnormalities may occur.
Precautions:
- Cardiovascular Disease: Use with caution in patients with a history of heart disease.
- Pregnancy: Rexigo is contraindicated during pregnancy as it may harm the fetus.
- Liver Impairment: Dose adjustments may be necessary in patients with liver dysfunction.
Storage:
Store Rexigo 120mg Tablets at room temperature (20°C to 25°C), away from light and moisture. Keep out of reach of children.
Conclusion:
Rexigo 120mg Tablets are an effective treatment for advanced prostate cancer and uterine fibroids. Monitoring for side effects, particularly cardiovascular and bone health, is essential during treatment.
View More